Precise epidermal delivery v20151005. © Pantec Biosolutions AG, 2015 All rights reserved...

Precise epidermal delivery

v20151005

© Pantec Biosolutions AG, 2015 All rights reserved Confidential slide 2

BEST-IN-CLASS

LASER-ASSISTED

EPIDERMAL DRUG DELIVERY

EPIDRUG™ & EPIMMUN™


Company profile

Location Ruggell, Liechtenstein

Foundation 2005 Dec.

Key assets - proprietary technology in epidermal delivery of

immunogens and drugs- portfolio of granted patents

and patent applications- EPIMMUN™: promising pre-

clinical results for delivery of variety of immunogens

- EPIDRUG™: clinical proof of concept for several drugs

Investors Private investors, VC company


P.L.E.A.S.E. = Precise Laser EpidermAl System

The only existing Ablative Laser Class 1 Full delegation - to be used by non-doctoral staff

No safety precautions required

User-friendly interface for easy programming

Small and mobile for easy use

Precise and painless delivery

Patent protected

Medical CE marked

Pantec’s device – P.L.E.A.S.E. Professional


EPIDRUG™ and EPIMMUN™ allows for optimal, dose-

controlled delivery of various drug and immunogen

substances into targeted skin layers offering an optimal

safety profile and in case of EPIMMUN™ inducing an active

immune-response and triggering a laser adjuvant effect.

Applications– EPIDRUG™ & EPIMMUN™


Precise and reproducible formation of micropores in desired skin layer

Topical administration of substance

Efficient delivery of substance through micropores and uptake relevant immune cells or receptors

EPIMMUN™ and EPIDRUG™ Process


We love micro-Pores!

Laser-assisted generation of micropores – the basis of the P.L.E.A.S.E. platform


EPIMMUNTM EPIDRUG™

EPIMMUN™ and EPIDRUG ™ allow for precise, dose-controlled delivery of various substances into targeted skin layers, offering an optimal safety profile.


+ Immune

stimulant effect; laser adjuvant effect


P.L.E.A.S.E.Precise Laser

EpidermAl SystEm


Precise micropore depth - delivery to target skin layers


200 mm

60 mm

• Easy to use, needle-less, painless, well-tolerated

• Reproducible formation of micropores• Precise depth

• Desired skin layers

• Induction of strong immune response (EPIMMUN™ only)• Precise immunogen delivery to target immune cells

• Immune-stimulant effect

Key advantages of EPIMMUN™ and EPIDRUG™


Market and Fields of ApplicationOncology active Immunotherapy

WW sales in 2014 of $ 41 billion1

Cancer immunotherapy is „ breakthrough treatment of the year 2013“ Checkpoint inhibitors and their combination with cancer active immunotherapies will substantially

contribute to expected growth of the market High medical need for effective immunogen delivery to target immune cells

Preventive and therapeutic vaccines WW sales of $ 33 billion in 2014 expected to grow to $56 billion in 20192

Needle-less delivery systems are highly needed, particularly in the developing world

Allergy immunotherapy WW sales of $ 1,1 billion in 20143

Highly underserved market – only 2% of allergic patents are currently treated because of cumbersome treatment schedules (>50 injections) over long period (>3 years)

Autoimmune disease drugs WW sales expected at $ 61 billion in 20174

Unmet medical need for local targeted delivery (reduce side effects of systemic drug administration)

Combined market potential > $100 billion1 Global & USA Cancer Immunotherapy Market Analysis to 20202 Markets and Markets 2015, „Vaccine market by technology – Forecast to 20193 ALK, Annual Report 20144 GBI Research, Autoimmune Disorders Therapeutics Market to 2017


Business Model

Formation of partnerships with biotech and pharmaceutical companies for commercialization of combination products using EPIDRUG™ or EPIMMUNTM together with their proprietary drug or vaccine formulations

To achieve this objective, Pantec

will generate broad database of preclinical and clinical data with EPIDRUG™ and EPIMMUNTM in wide variety of indications in collaboration with (existing and newly formed) research partnerships with leading academic institutions and biotech companies

will use this database to convince pharma companies to combine their substances with EPIDRUG™ and EPIMMUNTM

will enter into licensing agreements with pharma partners in return for upfront and milestone fees as well as royalties


Revenue Generation

Sales of devices and consumables Short Term: Laser devices (and consumables) on rental or purchase basis for research

partners Mid Term: Sales of laser devices and consumables to clinical trial centers and pharma

companies conducting studies with partnered products

Cumulative sales revenues of ~ € 1,7 million projected until 2018 (2015: ~ € 500.000)

Long Term: After launch of partnered product(s) (first launch expected in 2019) substantial increase in sales of laser devices and consumables to end users (physicians)

Licensing revenues Upfront, Milestone and Royalty payments from pharma partners

Pantec has already signed three such licensing agreements with pharma and biotech companies


Financials – Financing RoundFinancing Volume: € 4 Million

Funding reach: end 2018

Use of Proceeds: Business development and marketing/sales activities to leading scientific research institutions

and biotech companies Support of research institutions to generate strong EPIDRUG™/EPIMMUNTM preclinical/clinical data

base Business development for further pharma partnerships Engineering and design of next generation laser device Maintenance and Extension of IP portfolio

Key milestones Successful clinical study as part of existing EPIDRUG™ Pharma collaborations mid of 2016 First clinical data with EPIMMUNTM by end of 2016 Pharma partnership for EPIMMUNTM in 2017 Operational profitability in 2019

Exit potential – As a profitable Medtech company with significant growth potential, Pantec

would be an attractive M&A partner for Medtech and pharma companies would be an attractive investment case to go public


Reinhard Braun, Co-Founder, President and CEO Founder, President and CEO of Pantec Engineering AG Engineering Degree in Electronics

Christof Böhler, PhD, Co-Founder, Exec. Director Business Development CEO at Pantec Biosolutions from 2006 to 2014 PhD in Chemistry and executive degree in International Management

Elmira Lechat, MD, MBA, Medical Director Clinical Services Supervisor/Medical Scientific Expert at Medtronic Assistant at European Respiratory Society

Martin Steiner, PhD, MBA, Business Development EPIMMUNTM

Consultant to biotechnology companies Founder and CEO of two biotechnology companies PhD in Microbiology and Genetics and MBA

Tobias Bächle, Sales Director Senior Regional Sales Manager at Bio Separations GmbH and Macherey-Nagel AG Engineering Degree in Chemistry

Management Team


Laser platform developed at high quality standards P.L.E.A.S.E. laser platform developed, manufactured and medical CE-marked Established quality management system, ISO certification

Pharma collaborations in place Collaborations with Takeda, Ratiopharm and Oncosynergy (Biotech) actively running First-mover and pioneer in epidermal drug delivery for dermatology and immunotherapy

Strong IP position established Portfolio of patents granted or filed to protect laser device, as well as EPIDRUG™ and EPIMMUN™ Profound technological and application know-how

Promising preclinical data EPIMMUN™ concept successfully demonstrated in several animal studies Activation of relevant immune cells and induction of strong immune response by EPIMMUNTM

Clinical experience Completed clinical studies EPIDRUG™ prove safe, well-tolerated and reproducible laser microporation Ongoing clinical project with Takeda Pharmaceuticals

Strong scientific network Collaborations with leading research groups in different fields of immunotherapy established Several devices sold or rented to academic institutions and biotech companies

Key achievements to date


Investment Considerations

Proprietary, widely-applicable platform technology EPIDRUG™ and EPIMMUN™ are pre-clinically and clinically tested with different substances

for several different indications

Focus on rapidly –growing immunotherapy market Pantec is a leading first-mover and pioneer with proprietary technology and know-how Pantec has extensive network of leading scientific research groups and key opinion leaders Immunotherapy and vaccine market currently more than 75 billion

Management team with extensive know-how and experience Multi-year experience in various senior management roles with biotechnology,

pharmaceutical and medical technology companies

Financially attractive, low-risk investment Low technology risk – clinical experience shows excellent safety profile Existing partnerships with pharma and biotechnology company Platform applicable to a wide range of indications with large market potential

Attractive Exit potential Early break even (i.e. before partnered products enter market) Attractive M&A partner or IPO candidate

Precise epidermal delivery v20151005. © Pantec Biosolutions AG, 2015 All rights reserved...

Documents

Transcript of Precise epidermal delivery v20151005. © Pantec Biosolutions AG, 2015 All rights reserved...